Basic Information
Evrenzo
Regulatory Information
EMEA/H/C/004871
Authorised
August 18, 2021
June 24, 2021
6
April 8, 2025
Company Information
the netherlands
Sylviusweg 62 2333 BE Leiden
ASTELLAS PHARMA EUROPE B.V.
Drug Classification
Additional Monitoring
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Evrenzo is indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (CKD).
Overview Summary
Evrenzo is a medicine used in adults to treat the symptoms of anaemia (low red blood cell counts) caused by chronic kidney failure (long-term, progressive decrease in the ability of the kidneys to work properly). Evrenzo contains the active substance roxadustat.